Skin reactivity to autologous bacteria isolated from respiratory tract of patients with obstructive pulmonary disease

Similar documents
an inflammation of the bronchial tubes

INTRODUCTION TO UPPER RESPIRATORY TRACT DISEASES

The Bacteriology of Bronchiectasis in Australian Indigenous children

Community Acquired Pneumonia. Abdullah Alharbi, MD, FCCP

Session Guidelines. This is a 15 minute webinar session for CNC physicians and staff

JAC Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections

RESPIRATORY TRACT INFECTIONS. CLS 212: Medical Microbiology

Airway Bacterial Concentrations and Exacerbations of Chronic Obstructive Pulmonary Disease

Respiratory Pathogen Panel TEM-PCR Test Code:

Work-up of Respiratory Specimens Now you can breathe easier

Work up of Respiratory & Wound Cultures:

Unit II Problem 2 Pathology: Pneumonia

Protocols for Laboratory Verification of Performance of the BioFire FilmArray Pneumonia Panel

Babak Valizadeh, DCLS

Chapter 10 Respiratory System J00-J99. Presented by: Jesicca Andrews

PNEUMONIA. I. Background 6 th most common cause of death in U.S. Most common cause of infection related mortality

Critical Care Nursing Theory. Pneumonia. - Pneumonia is an acute infection of the pulmonary parenchyma

Bronchiectasis Domiciliary treatment. Prof. Adam Hill Royal Infirmary and University of Edinburgh

Table S1. Data on IgG substitution for participants that were included in the per protocol analysis (n=62/arm).

Upper...and Lower Respiratory Tract Infections

The Importance of Appropriate Treatment of Chronic Bronchitis

Normal Human Flora. (Human Microbiome) Dr.Sarmad M.H. Zeiny Baghdad College of Medicine

Integrated Cardiopulmonary Pharmacology Third Edition

Streptococci facultative anaerobe

PNEUMONIA IN CHILDREN. IAP UG Teaching slides

Microbiome and Asthma

THE PHARMA INNOVATION - JOURNAL Acute exacerbation of chronic obstructive pulmonary disease, caused by viruses: the need of combined antiinfective

Upper Respiratory Tract Infections

RESPIRATORY TRACT INFECTIONS. CLS 212: Medical Microbiology Zeina Alkudmani

POLICY FOR TREATMENT OF LOWER RESPIRATORY TRACT INFECTIONS

Protocols for Laboratory Verification of Performance of the BioFire FilmArray Pneumonia Panel plus

Respiratory System Virology

Upper Respiratory Tract Infections / 42

Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 April - 30 June 2014

Treatment of febrile neutropenia in patients with neoplasia

COPD guidelines in relation to infections: a critical analysis

PIDS AND RESPIRATORY DISORDERS

Respiratory tract infections. Krzysztof Buczkowski

Epiglottitis. Bronchitis. Bronchiolitis. Pneumonia. Croup syndrome. Miss. kamlah 2

CHEST VOLUME 117 / NUMBER 4 / APRIL, 2000 Supplement

COPD Treatable. Preventable.

Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 st January 31 st March 2015

IgE-mediated allergy in elderly patients with asthma

Creating a User Defined Pneumonia-Specific Syndrome in ESSENCE. Preventive Medicine Directorate September 2016

11/19/2012. The spectrum of pulmonary diseases in HIV-infected persons is broad.

JMSCR Vol 04 Issue 12 Page December 2016

HYPOCHLOROUS ACID (HOCl) Our Body's immune system protector in a BOTTLE

Downloaded from:

Nosocomial Pneumonia. <5 Days: Non-Multidrug-Resistant Bacteria

The Respiratory System

Pneumonia Aetiology Why is it so difficult to distinguish pathogens from innocent bystanders?

BACTERIOLOGY PROGRAMME AND PLAN OF TEACHING 3 rd Semester (academic year )

Management of Acute Exacerbations

CHMP List of questions

This activity is jointly provided by Global Education Group and Educational Awareness Solutions. Copyright 2018.

POLICY FOR TREATMENT OF UPPER RESPIRATORY TRACT INFECTIONS

Medical Bacteriology- Lecture 13 Gram Negative Coccobacilli Haemophilus Bordetella

Hospital-acquired Pneumonia

Nursing care for children with respiratory dysfunction

Slide 120, Lobar Pneumonia. Slide 120, Lobar Pneumonia. Slide 172, Interstitial Pneumonia. Slide 172, Interstitial Pneumonia. 53 Year-Old Smoker

SUPPLEMENTARY MATERIAL

Microbiology / Active Lecture Questions Chapter 15 / Microbial Mechanisms of Pathogenicity 1 Chapter 15 / Microbial Mechanisms of Pathogenicity

Running head: COMMON COLD AND BRONCHITIS 1

PULMONARY EMERGENCIES

Respiratory System. Respiratory System Overview. Component 3/Unit 11. Health IT Workforce Curriculum Version 2.0/Spring 2011

Respiratory Pathology. Kristine Krafts, M.D.

Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study

Topical areas of fundamental and applied research VI

Pathology of Pneumonia

Epidemiology and Etiology of Community-Acquired Pneumonia 761 Lionel A. Mandell

THERAPY ANALYSIS. Dr. Daniela and Dr. Tony Katzmayr. Pulmological Specialist Practice. Innsbruck / Austria

Infections of the head, neck, and lower respiratory tract

MANAGEMENT OF RHINOSINUSITIS IN ADULTS IN PRIMARY CARE

NON-CF BRONCHIECTASIS IN ADULTS

Dr Rodney Itaki Lecturer Division of Pathology Anatomical Pathology Discipline

Medical / Microbiology

66YM Chronic obstructive pulmonary disease annual review. H Chronic obstructive pulmonary disease

Charles Krasner, M.D. University of NV, Reno School of Medicine Sierra NV Veterans Affairs Medical Center

Antibiotics, Expectorants, and Cough Suppressants. Center For Cardiac Fitness Pulmonary Rehab The Miriam Hospital

5/5/2013. The Respiratory System. Chapter 16 Notes. The Respiratory System. Nasal Cavity. Sinuses

PBL RESPIRATORY SYSTEM DR. NATHEER OBAIDAT

Healthcare-associated infections acquired in intensive care units

Respiratory Diseases and Disorders

RESPIRATORY BLOCK. Bronchial Asthma. Dr. Maha Arafah Department of Pathology KSU

Respiratory diseases in Ostrołęka County

ZINEX. Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg

Medical Bacteriology Lecture 15

Bacterial Mechanisms of Pathogenicity. 2 nd Lecture

Online Data Supplement. Impulse Oscillometry in Adults with Bronchiectasis

(cilia) that help sweep away fluids and/or particles International Journal of Pharmaceutical Sciences and Research 2055

Clinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy

Sputum Screening by Nomarski Interference Contrast

Pneumonia. Definition of pneumonia Infection of the lung parenchyma Usually bacterial

UPPER RESPIRATORY TRACT INFECTIONS. IAP UG Teaching slides

Self-study course. Pneumonia

Potential Reimbursement CPT Codes

COPD exacerbation. Dr. med. Frank Rassouli

PATHOLOGY & PATHOPHYSIOLOGY

320 MBIO Microbial Diagnosis. Aljawharah F. Alabbad Noorah A. Alkubaisi 2017

Transcription:

Skin reactivity to autologous bacteria 149 Original Article Skin reactivity to autologous bacteria isolated from respiratory tract of patients with obstructive pulmonary disease J. Halasa 1, M. Halasa 2 1 Department of Microbiology and Immunology 2 Department of General Pathology, Pomeranian Medical University, Szczecin, Poland Abstract: Bacterial flora of various strains was isolated from sputum and in some cases from BAL fluid of 75 patients with obstructive pulmonary disease experiencing dyspnea symptoms accompanying infections of respiratory tract. Among strains recognized traditionally as pathogenic in respiratory tract, we also isolated various strains typically called normal oropharyngeal flora, physiologic or non-pathogenic bacteria. Those latter strains used in the skin tests in autologous manner for each patient had the property of provoking early (15 min) and late (24-48 h) reactions. Early reactivity resembles that induced in the tests with airborn allergens. This suggests a potentially important role of those currently ignored strains in pathogenesis of obstructive pulmonary disease. Key words: Obstructive pulmonary disease, pathogenic flora, physiologic flora, skin tests. Introduction In several publications Norn and his group provided evidence that bacteria have the ability to induce histamine release or to enhance the inflammatory mediator release [1-4]. Such biological effects depend on two major mechanisms, i.e. IgE-mediated and non IgE-mediated reactions. The latter includes carbohydrate-lectin mediated reactions [3]. Our own observations concerning skin reactivity of the patients with obstructive pulmonary disease (qualified either as COPD or asthma) to autologous bacteria isolated from their respiratory tract showed that the bacteria used in the skin tests can provoke reactions of the immediate (15 min.), delayed (8-10 h) and late type (24-48h from introduction of the skin test). We found that different strains can provoke either all three types of reactions, two of them or just one, depending on the species of bacteria analyzed and on the individual patient s reactivity [5]. Bacteria growing extensively in the mucous secretions filling the respiratory tract of the patients with obstructive pulmonary disease are very difficult to eradicate with antibiotics [6-8]. These bacteria, that act on the patients respiratory tract not only by the mean of toxins and enzymes released, but also through induction of the allergic and para-allergic reactivity, need to be more thoroughly investigated. This study has been designed to show skin test reactivity to both pathogenic and nonpathogenic autologous bacteria isolated from the respiratory tract of individual patients. Materials and methods Patients We studied 75 patients chronically suffering from obstructive pulmonary disease ranging between 18 and 65 years of age with the average age of 48 years. The duration of the disease ranged between 3 and 20 years; the average duration was 8 years. All of the patients were hospitalized, most of them repeatedly, because of the marked increase in dyspnea associated with signs and symptoms of infection. All patients were included in the trial and tested during infectious exacerbation of the

150 M. Halasa et al. disease. Such exacerbations were diagnosed mainly based on the presence of: increased dyspnea, productive cough with muco-purulent sputum, increased sputum volume, increased sputum purulence, fever, malaise. In the course of their disease patients received typical treatment including bronchodilatating and antiinflammatory drugs and antibiotics. During the period of the trial and at least for 2 weeks prior to their introduction to it, patients did not receive systemic glucocorticoids. In the medical records of most of the patients, the obstructive pulmonary disease was associated with diagnoses varying over the course of the disease. Diagnoses were also depending on the medical facility patients were diagnosed at. First clinical diagnosis was usually spastic bronchitis followed by the diagnosis of asthma or COPD. Immediately before the trial all patients included were diagnosed as suffering from COPD. The diagnosis was based on American standards [9]. Tested material Sputum Throat and nasal swabs BAL (broncho-alveolar lavage) in 1/3 of patients Tested material, except for BAL, was obtained repeatedly (2-3 times) from each patient during disease exacerbation, and cultured in the routine media for aerobic and anaerobic bacteria. If patient received antibiotics, bacteriological tests were performed at least two weeks after withdrawal of such treatment. Skin tests We have tested skin reactivity of each patient to autologous bacteria. Each cultured bacterial strain was separated, killed with formaldehyde and suspended in saline at the concentration of 3x10 5 cells per ml. Skin tests were performed by injecting 0.05 ml of bacterial suspension intradermaly on the forearm. As a positive control we used 0.05 ml of 0.1% histamine and the negative control was the injection of 0.05 ml of saline solution. Early skin reactivity was assessed after 15 minutes and the late one after 24 hours. Early skin reactivity was assessed based on the diameter of the wheal and flare independently. As a positive result in early skin reactivity we accepted the wheal and flare measuring of at least half the size of positive control, assumed that negative control showed no reaction. As a strong reaction we accepted the wheal and flare of the size at least as large as provoked by histamine. For the late type of reaction only flare was measured. The criteria for positive reaction of the late type were: positive diameter no less then 5 mm., strong positive diameter no less than 10 mm. Results As we have shown in our results (Table 1) a variety of bacteria species, able to provoke some degree of skin reactivity in autologous tests, can be found in Table 1. Prevalence of bacterial strains provoking any type of autologous skin test reactions found in total 75 patients. Each strain provoked positive skin tests of either early, late or both types of reactions. Pathogenic bacteria strains Staphylococcus coagulase (+) positive 45.3 (34) Moraxella catarrhalis 26.7 (20) Haemophilus influenzae 17.3 (13) Streptococcus pneumoniae 12.0 (9) Haemophilus parainfluenzae 10.7 (8) Klebsiella pneumoniae 2.7 (2) Physiologic (nonpathogenic) bacteria strains Streptococcus viridans 74.7 (56) Neisseria species 56.0 (42) Staphylococcus coagulase (-) negative 17.3 (13) Streptococcus nonhemoliticus 17.3 (13) Streptococcus beta-hemoliticus type B 10.7 (8) Escherichia coli 9.3 (7) Corynebacterium species 6.7 (5) Candida albicans 2.7 (2) Proteus vulgaris 1.3 (1) Pseudomonas aeruginosa 1.3 (1) J Invest Allergol Clin Immunol 2004; Vol. 14(2): 149-153 2004 Esmon Publicidad

Skin reactivity to autologous bacteria 151 Table 2. Typical reactivity to own bacterial strains cultured from respiratory tract of the 50 year old patient suffering from dyspnea for 12 years, repeatedly hospitalized in the past. Pathogenic strains of bacteria Early reactions Late reactions Moraxella catarrhalis 10/20 20 Staphylococcus aureus 10-25 5 Streptococcus viridans 15/25 10 Staphylococcus epidermidis (coagulase negative) 7/25 10 Neisseria species 6/12 20 Controls Saline 0/0 0 Histamine 7/25 0 x/ wheal size in mm. /y flare size in mm. the respiratory tract of the patients with obstructive pulmonary disease. Usually several different species can be isolated from one patient. Some of them can be found more commonly than others. An example is given in table 2 showing the skin reactivity to autologous bacteria isolated from the respiratory tract of a patient with obstructive pulmonary disease. Most common bacteria belonging to a group usually called nonpathogenic, normal or physiologic bacteria in the respiratory tract were: Streptococcus viridans and Neisseria species. Other nonpathogenic bacteria found in a number of patients were: Staphylococcus coagulase negative, Streptococcus nonhemoliticus, Streptococcus b-hemoliticus type B and Escherichia coli. Among pathogenic bacteria Staphylococcus aureus and Haemophilus influenzae were the most prevalent, whereas Streptococcus pneumoniae were found rarely, and Klebsiella pneumoniae sporadically. Nonpathogenic bacteria most frequently provoking strong early skin test reactivity were: Staphylococcus coagulase negative, Neisseria species and Streptococcus viridans (Table 3). The same strains gave most frequently strong positive reactions of the late type (Table 4). Among Table 3. Prevalence of bacterial strains provoking strong autologous positive skin tests reactions of the early type in 75 patients. Reactions were measured 15 min. from the introduction of the test material. Pathogenic strains of bacteria Staphylococcus coagulase (+) positive 21.3 (16) Haemophilus influenzae 5.3 (4) Streptococcus pneumoniae 5.3 (4) Haemophilus parainfluenzae 4.0 (3) Moraxella catarrhalis 2.7 (2) Staphylococcus coagulase (-) negative 20.0 (15) Neisseria species 13.3 (10) Streptococcus viridans 10.7 (8) Escherichia coli 6.7 (5) Streptococcus nonhemoliticus 4.0 (3) Corynebacterium species 2.7 (2) Candida albicans 2.7 (2) Pseudomonas aeruginosa 2.7 (2) Streptococcus beta-hemoliticus type B 1.3 (1)

152 M. Halasa et al. Table 4. Prevalence of bacterial strains provoking strong autologous positive skin tests reactions of the late type in 75 patients. Reactions were measured 24-48 h from introduction of the test material. Pathogenic strains of bacteria Staphylococcus coagulase (+) positive 13.3 (10) Haemophilus influenzae 8.0 (6) Moraxella catarrhalis 8.0 (6) Streptococcus pneumoniae 5.3 (4) Haemophilus parainfluenzae 4.0 (3) Staphylococcus coagulase (-) negative 17.3 (13) Neisseria species 10.7 (8) Streptococcus viridans 10.7 (8) Escherichia coli 6.7 (5) Streptococcus nonhemoliticus 4.0 (3) Streptococcus beta-hemoliticus type B 2.7 (2) Corynebacterium species 2.7 (2) Proteus vulgaris 1.3 (1) Pseudomonas aeruginosa 1.3 (1) pathogenic bacteria strong early skin test positive reactions were provoked mainly by Staphylococcus aureus and less commonly by: Haemophilus influenzae, Streptococcus pneumoniae, Haemophilus parainfluenzae and Moraxella catarhalis. Similar pattern among these bacteria is characteristic for the positive skin tests results of a late type except for more common strong late reactivity with Moraxella catarrhalis strains. Most patients responded to their own bacteria with both early and late skin test reactions. Only in some cases we observed either early or late reaction. Discussion In physiological conditions the lower respiratory tract is free of bacteria. Bacteria can be found there as a result of acute infection with bacterial strains of: Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and increasingly common in the recent years: Chlamydia, Mycoplasma and Legionella. Bacterial presence in the lower respiratory tract can also be secondary to viral infections that damage ciliated bronchial epithelium and increase mucus production as a result of inflammation. Excessively secreted mucus may become a hideout and feeding medium for bacteria aspirated to the bronchial tree. Regardless of the mechanism of introduction, bacterial presence in the lower respiratory tract is generally related to some kind of inflammatory response. The airways of smokers seem to be the exception, because normal oropharyngeal flora can be found there in asymptomatic smokers as well as in smokers with chronic bronchitis [10]. Bacteria isolated from lower respiratory tract belong not only to the group of commonly recognized pathogens. Also so called physiological or normal strains can inhabit the bronchial tree using mucus as a growth medium. Such strains belong mainly to: Streptococcus viridans and Neisseria catarrhalis, which is confirmed by our results. These nonpathogenic bacteria have a strong tendency to provoke early and late skin tests reactions, as it is also documented in this experiment. This indicates some kind of bacteria induced mediator release, possibly involved also in the pathomechanisms in the bronchi. Acting in concert with infections caused by viruses and classically pathogenic bacteria, they may create a vicious circle of the respiratory tract inflammatory reactions (allergic, pseudoallergic and infectious) which could be hard to break. Management of such states is very difficult because the antibiotics administered can just reduce, but usually not eliminate the infection [7,8]. Furthermore, antibiotics can reach only those bacteria that grow directly on the surface of the mucus membrane or in the tissue, but fail to eradicate bacteria hidden in the excessively produced mucus. Concentration of antibiotics in the mucus cannot reach effective level. Streptococci deserve separate analysis. Their common presence and the ability to provoke strong reactions of the early as well as the late types, point to the their possible role in pathogenesis of the obstructive pulmonary disease. Very interesting finding of basophilbound IgE and serum IgE directed against Streptococcus pneumoniae in patients with chronic bronchitis during J Invest Allergol Clin Immunol 2004; Vol. 14(2): 149-153 2004 Esmon Publicidad

Skin reactivity to autologous bacteria 153 acute exacerbations, also suggests non-classical pathomechanisms related to streptococcal infection [11]. Our trial findings, that Streptococcus viridans, but also Neisseria spp. and other nonpathogenic bacteria have the ability to provoke early and late autologous skin test reactions may suggest their involvement in pathogenesis of COPD with infectious exacerbations complicated by obstruction in the airways. On the other hand, isolating such flora not only in the course of chronic bronchitis in smokers but also in asymptomatic smokers, as shown by Ovarfordt [10], can suggest their lack of involvement in the pathomechanism of bronchial obstruction. One of the possible explanations of this contradiction may be derived from the outcome of our study. If we assume, based on our results, that normal flora can provoke allergic or pseudoallergic type of reactions, not only the presence of this bacteria in the bronchi may decide of the development of spastic symptoms. Also hyperreactivity to these species is needed, which depends on allergic or pseudoallergic reactions. Currently Streptococcus viridans, like other nonpathogenic bacteria, are not considered to be a factor leading to development of obstructive pulmonary disease [12, 13]. However, difficulties to verify the presence or absence of nonpathogenic species and subtypes in the airways may explain this opinion. It should be recalled that in the bacteriological laboratories, examination of e.g. Streptococcus viridans or Neisseria species is usually followed only by the statement: physiological flora was found or no pathogenic bacteria were found. This contributes to the medical professions, including lung specialists attempting to explain the pathogenesis of COPD, to ignore the colonization of the bronchi by this bacteria. The results presented herein should induce a more exhaustive analysis of the presence of so called nonpathogenic bacterial flora found in the lower respiratory tract of patients with obstructive pulmonary disease. Such analysis may lead to better explanation of the role of bacteria in bronchial asthma [14] and in a larger sense, in the obstructive lung disease [15]. This should also induce a thorough review of the value of vaccine use in asthma with symptom exacerbations during infections [5, 16]. Microorganisms induce and enhance histamine release. International Review of Allergology & Clinical Immunology 1997;3(1):8-11 4. Clementsen P., Milman N., Struve-Cristensen E., Nuchel Petersen B., Pedersen M., Bisgaard H., Permin H., Norn S.: Bacteria-induced histamine release from human bronchoalveolar cells and blood leukocytes. Allergy 1991;46:45-51 5. Halasa J., Halasa M., Wojciechowska W., Podkowinska I., Kucharska E.: Clinical efficiency of autovaccine in the test treatment of infectious nonatopic asthma and COPD double blind placebo controlled trial. Allergia, Astma, Immunologia 2001;6(2):43-7 6. Chodosh S.: Treatment of acute exacerbations of chronic bronchitis: state of the art. Am.J.Med. 1991;91:87-92 7. Murphy T.F., Sethi S. Niederman M.S.: The role of bacteria in exacerbations of COPD. A constructive view. Chest 2000;118:204-209 8. Grossman R.F.: The value of the antibiotics and the outcomes of antibiotic therapy in exacerbation of COPD. Chest 1998;113(Suppl.4):249-55 9. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am.Rev.Respir.Dis. 1995;152:78-83 10. Ovarfordt J., Riise G.C., Andersson B.A., Larsson S.: Lower airway bacterial colonization in asymptomatic smokers and smokers with chronic bronchitis and recurrent exacerbations. Respir. Med. 2000;94(9):881-7 11. Kjergard L.L., Larsen F.O., Norn S., Clementsen P., Skov P.S., Permin H.: Basophil-bound IgE and serum IgE directed against Haemophilus Influenzae and Streptococcus pneumoniae in patients with chronic bronchitis during acute exacerbations. APMIS 1996;104:61-67 12. Sethi S., Muscarella K., Evans N., Klingman K.L., Grant B.J., Murphy T.F.: Airway inflammation and ethiology of acute exacerbation of chronic bronchitis. Chest 2000;118:1557-65 13. Sethi S., Murphy T.F.: Bacterial infection in chronic obstructive pulmonary disease in 2000: a State of the Art Review. Clin.Microbiol.Rev. 2001;14(2):336-63 14. Oeling A.K.: Bacterial infection as an important triggering factor in bronchial asthma. J. Investig. Allergol. Clin. Immunol. 1999;9(1):6-13 15. Malling H.J.: Bacterial vaccines: anything but placebo. Allergy 2000;55:214-18 16. Bousquet J., Lockey R.F., Malling H.J.: WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998;53(Suppl.44):1-42 References 1. Norn S., Skov P.S., Jensen C.: Bacterial and viral infections in asthma. Allergy Today 1985;1:37-9 2. Norn S.: A medical hypothesis. Bacteria induced histamine release: possible relationship to asthma. Rev. Fr. Allerg. 1988;28:199-203 3. Norn S., Clementsen P., Larsen F.O., Permin H., Skov P.S.: Pathophysiological mechanisms in obstructive lung diseases: Dr. Maciej Halasa MD, PhD Department of General Pathology Pomeranian Academy of Medicine Al. Powstancow Wlkp. 72 70-111 Szczecin Tel.: +48 601 567 339 (mobile) +48 91 466 1557 (work) E-mail: maciupam@sci.pam.szczecin.pl